DJI accueille des cinéastes et des visionnaires lors d'une session au Venice Production Bridge pendant la 83e Mostra internationale du film de Venise

Nouvelle génération, nouveau langage cinématographique : Osmo Pocket 4P ouvre une nouvelle conversation sur la narration, la liberté créative et les outils professionnels.

VENISE, Italie, 9 septembre 2026 /PRNewswire/ -- DJI, le leader mondial des drones civils et de la technologie de caméras créatives, a organisé la « Filmmakers & Visionaries Session », un forum professionnel tenu pendant le Venice Production Bridge lors de la 83e Mostra internationale du film de Venise. La rencontre a réuni de jeunes réalisateurs et directeurs de la photographie afin d'explorer une question à laquelle l'industrie commence seulement à répondre : lorsque une caméra de cinéma tient dans la paume de la main, comment le langage même du cinéma évolue‑t‑il ?

De Cannes à Venise : Une vision unifiée

La session Venice Production Bridge a poursuivi le voyage créatif entamé cette année par la série Osmo Pocket. Après la présentation mondiale à Cannes en mai, DJI a confié Osmo Pocket 4P à deux des voix visuelles les plus singulières du cinéma, chacune travaillant de manière indépendante sur des continents différents. Les résultats ont révélé une convergence frappante.

Dans « FAMILIARITÉ », l'actrice Isabelle Huppert, récompensée à Cannes et à Venise, tient le premier rôle et signe la création d'une méditation inédite sur la littérature et la mémoire, filmée entièrement avec Osmo Pocket 4P. Parallèlement, le directeur de la photographie japonais renommé Mikiya Takimoto a imaginé et réalisé « Looking for Her », un récit dans le style road movie se déroulant dans une ville historique d'extraction d'argent, qui retrace une quête silencieuse de lien humain, également entièrement tourné avec Osmo Pocket 4P. Ce qui a émergé de ces deux processus créatifs indépendants, c'est une conviction commune : une caméra suffisamment légère pour disparaître dans la main ne fait aucun compromis sur la profondeur émotionnelle ni sur la précision technique. Les deux films démontrent toutes les capacités de la narration cinématographique condensées dans un format qui tient dans la poche. À Venise, cette vérité créative intime est devenue une question publique pour l'industrie.

Projections d'avenir : De la théorie à la pratique

La session est conçue comme un véritable dialogue professionnel, fondé entièrement sur la pratique de la réalisation plutôt que sur la démonstration de produit. Quatre courts-métrages réalisés par un groupe international de directeurs de la photographie émergents ont été projetés : Gabriele Mencaroni et Alessandro Tempestini (Italie), Liu Yadi (Chine/France) et Zhou Chengzhou (Chine/Pays-Bas). Leur travail collectif couvrait le film expérimental, la production commerciale et les documentaires reconnus en festival, une diversité qui reflète une génération évoluant au‑delà des frontières créatives traditionnelles.

À l'issue de la projection et d'une démonstration de tournage en direct, trois directeurs de la photographie de renommée internationale ont proposé une analyse professionnelle rigoureuse : Valentin Vignet, un directeur de la photographie français connu pour son travail sur Faces Places et le court métrage Nefta Football Club, nommé aux Oscars ; Cristiano Di Nicola, un directeur de la photographie italien multi‑récompensé, présent à Venise avec « L'Estranea » en compétition officielle ; et Michele D'Attanasio, double lauréat du David di Donatello, connu pour des films comme Veloce come il vento, Freaks Out et L'ombra di Caravaggio. Tous trois, forts de leur expérience à la tête de productions de grande envergure, ont évalué la narration visuelle des jeunes réalisateurs au regard des exigences intransigeantes du cinéma professionnel, démontrant que la sophistication technique de leur travail était à la hauteur des standards traditionnels de la cinématographie plutôt qu'elle ne les compromettait.

La table ronde : Discussion sectorielle sur la redéfinition du cinéma

L'élément central était une table ronde : « Comment une nouvelle génération redéfinit-elle le cinéma ? » La conversation a entremêlé les points de vue distincts de directeurs de la photographie chevronnés et de réalisateurs émergents, en explorant de manière fluide quatre dimensions fondamentales : comment des outils compacts et stabilisés par nacelle redéfinissent la relation entre la caméra, l'interprète et l'environnement ; si des équipements plus légers et plus flexibles démocratisent la réalisation professionnelle tout en exigeant une discipline visuelle accrue ; comment les flux de production et les dynamiques sur le plateau se transforment avec des configurations légères ; et, en fin de compte, si un outil peut réellement modifier le langage cinématographique lui‑même ou si l'idée visuelle doit toujours primer.

Valentin Vignet est revenu sur le changement de mentalité lorsque l'imposant dispositif de caméra disparaît du plateau : l'acteur n'a plus à s'adapter au matériel, et la caméra devient un témoin plutôt qu'un obstacle. « Ce qui m'a le plus frappé dans ces quatre courts métrages, c'est qu'aucun des réalisateurs n'a eu besoin de faire de compromis sur la qualité pour utiliser une caméra plus légère », a déclaré Cristiano Di Nicola. « Il y a eu tellement de plans que je ne pensais même pas possibles auparavant, et c'est parce que l'Osmo Pocket 4P vous libère en tant que cinéaste. Nous pouvons nous concentrer davantage sur la façon de raconter l'histoire, et plus particulièrement sur la façon de nous rapprocher de l'action, plutôt que sur l'installation du matériel. »

Pour des directeurs de la photographie transculturels comme Liu Yadi et Zhou Chengzhou, l'accent s'est déplacé : Comment les jeunes directeurs de la photographie peuvent‑ils préserver une véritable expression cinématographique malgré les contraintes serrées de budgets limités et d'équipes réduites au minimum ? La réponse a émergé naturellement au fil du dialogue : les normes professionnelles, la science des couleurs, la plage dynamique et la précision de stabilisation sont désormais dissociées de l'échelle des équipements. Un•e directeur•rice de la photographie travaillant seul•e dans un espace confiné peut déployer la même sophistication technique qu'une équipe hollywoodienne. La barrière à l'entrée a été abaissée, non pas en sacrifiant la qualité, mais en redistribuant l'endroit où cette qualité peut résider.

La session Venice Production Bridge organisée par DJI cristallise un moment où la question fondamentale du cinéma passe de « De quels équipements avons‑nous besoin ? » à « Que devient-il possible lorsque l'équipement cesse d'être un obstacle ? ». Osmo Pocket 4P est la réponse de DJI : une puissance d'imagerie professionnelle libérée de toute échelle industrielle, qui donne à chaque conteur, dans n'importe quel environnement, des ruelles étroites de Tokyo jusqu'à un canoë sur le lac paisible d'un jardin, les moyens d'apporter tout le poids technique et émotionnel du cinéma à sa vision. C'est une nouvelle ère définie par l'accessibilité, qui rend des outils de qualité cinéma accessibles à davantage de visionnaires et offre plus de liberté créative dans la manière dont ils racontent leurs histoires. Avec de plus petites caméras de cinéma, le véritable pouvoir de la technologie d'imagerie se révèle, non comme une contrainte pour l'imagination, mais comme une libération.

About DJI

Since 2006, DJI has led the world with civilian drone innovations that have empowered individuals to take flight for the first time, visionaries to turn their imagination into reality, and professionals to transform their work entirely. Today, DJI serves to build a better world by continuously promoting human advancement. With a solution-oriented mindset and genuine curiosity, DJI has expanded its ambitions into areas such as renewable energy, agriculture, public safety, surveying and mapping, and infrastructure inspection. In every application, DJI products deliver experiences that add value to lives around the world in more profound ways than ever before.

For more information, visit our:

Website: www.dji.com

Online Store: store.dji.com

Facebook: www.facebook.com/DJI

Instagram: www.instagram.com/DJIGlobal

X: www.x.com/DJIGlobal

LinkedIn: www.linkedin.com/company/dji

Subscribe to our YouTube Channel: www.youtube.com/DJI 

Share this article

BMO and REX Shares Launch MicroSectors™ 3× Long and -3× Short Communication Services (XLC) and Consumer Staples (XLP) ETNs (Cboe BZX: XLCU, XLCD, XLPU, XLPD)

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Bank of Montreal ("BMO") and REX Shares, LLC ("REX") announced today the launch of the following Exchange Traded Notes ("ETNs") issued by BMO:

The ETNs will start trading tomorrow on the Cboe BZX Exchange, Inc. under the applicable ticker symbol identified above. Each series of ETNs is intended to offer sophisticated investors three times leveraged long or short, as applicable, participation in the daily performance of the relevant index, before taking into account fees, charges and the decay effect caused by the daily resetting of the leverage.

The XLCU ETNs and the XLCD ETNs are linked to the VettaFi US Communications Fund-Tracking Index, a total return index created, sponsored and maintained by VettaFi LLC that tracks the performance of the State Street® Communication Services Select Sector SPDR® ETF (XLC) and is designed to provide exposure to the communication services sector of the S&P 500® Index through a single fund-tracking vehicle. The ticker symbol of the VettaFi US Communications Fund-Tracking Index is "VXLCF."

The XLPU ETNs and the XLPD ETNs are linked to the VettaFi US Consumer Staples Fund-Tracking Index, a total return index created, sponsored and maintained by VettaFi LLC that tracks the performance of the State Street® Consumer Staples Select Sector SPDR® ETF (XLP) and is designed to provide exposure to the consumer staples sector of the S&P 500® Index through a single fund-tracking vehicle. The ticker symbol of the VettaFi US Consumer Staples Fund-Tracking Index is "VXLPF."

The XLCU ETNs, XLCD ETNs, XLPU ETNs and XLPD ETNs further expand the sector coverage of the MicroSectors™ platform and reflect BMO and REX's continued commitment to broadening the range of leveraged daily trading tools available to sophisticated investors. The new ETNs follow a series of recent MicroSectors™ launches spanning semiconductors, high yield and investment grade corporate bonds, Brazilian, Japanese and Taiwanese equities, and the NYSE® MaNGoS+ Index.

Disclosures

The ETNs are not intended to be "buy and hold" investments and are not intended to be held to maturity. Instead, the ETNs are intended to be daily trading tools for sophisticated investors to manage daily trading risks as part of an overall diversified portfolio. The ETNs are designed to reflect a 3× leveraged long or short, as applicable, exposure to the performance of the relevant index on a daily basis, before taking into account the negative effect of the fees and charges. However, as a result of the daily resetting of the leverage, the returns on the ETNs over different periods of time can, and most likely will, differ significantly from three times the return on a direct long or short investment in the relevant index. The ETNs are designed to achieve their stated investment objectives on a daily basis. The performance of the ETNs over different periods of time can differ significantly from their stated daily objectives. The ETNs are considerably riskier than securities that have intermediate- or long-term investment objectives and are not suitable for investors who plan to hold them for a period of more than one day or who have a "buy and hold" strategy. Investors should actively and continuously monitor their investments in the ETNs on an intraday basis, and any decision to hold the ETNs for more than one day should be made with great care and only as the result of a series of daily (or more frequent) investment decisions to remain invested in the ETNs for the next one-day period. The ETNs are very sensitive to changes in the level of the relevant index, and returns on the ETNs may be negatively affected in complex ways by the volatility of the relevant index on a daily or intraday basis. It is possible that investors will suffer significant losses in the ETNs that provide leveraged long exposure even if the long-term performance of the relevant index is positive. Similarly, it is possible that investors will suffer significant losses in the ETNs that provide short leveraged exposure even if the long-term performance of the relevant index is negative. Accordingly, the ETNs should be purchased only by sophisticated investors who understand and can bear the potential risks and consequences of the ETNs that are designed to provide leveraged exposure to the long or short, as applicable, performance of the relevant index on a daily basis and that will be highly volatile and may experience significant losses, up to the entire amount invested, in a short period of time.

For additional information, including a discussion of the risks relating to an investment in the ETNs, please carefully read the applicable pricing supplement and related documents that we have filed with respect to the ETNs (each, an "ETN Prospectus"). Investors should review the relevant ETN Prospectus carefully prior to making an investment decision.

The ETN Prospectus relating to each series of ETNs can be found on EDGAR, the Securities and Exchange Commission (the "SEC") website at: www.sec.gov, as well as on the product websites at the following links: www.bmoetns.com and www.microsectors.com.

Bank of Montreal, the issuer of each series of ETNs, has filed a registration statement (including a pricing supplement, prospectus supplement and prospectus) with the SEC regarding each series of the ETNs. Please read those documents and the other documents relating to these offerings that Bank of Montreal has filed with the SEC for more complete information about Bank of Montreal and these offerings. These documents may be obtained without cost by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Bank of Montreal, and any agent or dealer that participated in the offering of the ETNs, will arrange to send the applicable pricing supplement, the prospectus supplement and the prospectus if so requested by calling toll-free at 1-877-369-5412.

The ETNs are senior, unsecured obligations of BMO, and are subject to BMO's credit risk.

Investment suitability must be determined individually for each investor, and the ETNs are not suitable for all investors. This information is not intended to provide and should not be relied upon as providing accounting, legal, regulatory or tax advice. Investors should consult with their own financial advisors as to these matters.

About REX Shares

REX Shares ("REX") offers a suite of exchange-traded products built for both active traders and long-term investors, spanning income, thematic, and leveraged strategies. Whether making short-term trades, generating income from volatility, or investing in digital assets and emerging themes like drones, REX empowers investors to act on strong market views.

For more information, please visit www.rexshares.com

REX Media Contacts: [email protected]

About BMO Financial Group

BMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.5 trillion as of July 31, 2026. Serving clients for more than 200 years, BMO provides a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services across Canada, the United States, and select markets globally. BMO is innovating for business value, by deploying and integrating human, digital and artificial intelligence to personalize client experiences, augment teams, and automate its business responsibly. Driven by its purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and stronger communities.

Bank of Montreal ETNs: [email protected], +1 (877) 369-5412

Internet: www.bmo.com

MicroSectors™ and REX™ are trademarks of REX. The trademarks have been licensed to BMO for use for certain purposes by REX. The VettaFi US Communications Fund-Tracking Index and the VettaFi US Consumer Staples Fund-Tracking Index are service marks of VettaFi and have been licensed for use by REX and BMO. The ETNs are not sponsored, endorsed, sold or promoted by REX or any of its affiliates or third-party licensors (collectively, "REX Index Parties"). REX Index Parties make no representation or warranty, express or implied, to the owners of the ETNs or any member of the public regarding the advisability of investing in securities generally or in the ETNs particularly or the ability of the indices to track general stock market performance.

SOURCE BMO Financial Group

Share this article

Samantha's House Golf Outing Raises Nearly $75,000 for Local Family in Need

Record-Setting Support with Keller & Keller Injury Lawyers: Samantha's House's 16th Annual Golf Outing Nets Nearly $75,000 for Central Indiana Child

INDIANAPOLIS, Sept. 9, 2026 /PRNewswire/ -- A single day of community engagement in Indianapolis resulted in nearly $75,000 raised to support a local family in crisis. The annual golf outing, hosted by Samantha's House with the support of Keller & Keller, serves as a direct financial bridge for neighbors facing extreme hardship. Learn more about the mission and how to contribute at Samantha's House.

The proceeds from the event are designated for a specific Central Indiana family navigating difficult circumstances. This year's fundraising total exceeded expectations, reflecting a heightened level of community involvement and a shared commitment to providing tangible relief. By focusing on direct assistance, the event ensures that the resources gathered translate immediately into necessary support for those facing immediate financial crisis. This model of localized fundraising bypasses traditional bureaucratic delays, delivering impact where it is most urgent.

"What makes the 16th annual golf outing so special is that it's not a faceless donation — it's neighbors showing up for a child in our own community," said Jim Keller, President of Samantha's House. "Every dollar raised today goes directly to a Central Indiana family who needed to know someone had their back."

The collaboration highlights the ongoing mission of Samantha's House to help families navigate crisis through localized, direct support.

Impact of community-led fundraising

- Direct Assistance: 100% of the nearly $75,000 in proceeds is allocated to a local family.

- Community Engagement: The 16th annual event saw record participation from local donors.

- Crisis Navigation: Funds provide a handicapped accessible vehicle for a family with a disabled child facing financial and transportation issues.

The success of this year's event underscores the power of local generosity. As financial pressures on families increase, the partnership between local businesses and non-profits remains a cornerstone of the regional social safety net. Keller & Keller continues to prioritize these community-led initiatives to ensure that local families do not have to face hardship alone.

This event is part of Keller & Keller's ongoing commitment to moving at the speed of culture for the local communities it serves. Learn more about the firm at Keller & Keller.

Adam Swartz

(317) 275-3016

SOURCE Keller & Keller Injury Lawyers

Share this article

Fastest-growing powersports retailer delivers record 511 new Harley-Davidson motorcycle sales; Black Hills Harley-Davidson ranks No. 1 nationally in year-to-date new-bike sales

CHARLOTTE, N.C. and STURGIS, S.D., Sept. 9, 2026 /PRNewswire/ -- Sonic Automotive, Inc. (NYSE: SAH), one of the nation's largest automotive and powersports retailers and the only automotive and powersports retailer recognized on Newsweek's 2026 "Most Trustworthy Companies in America" list, today announced that Sonic Powersports set another sales record at the 86th annual Sturgis Motorcycle Rally, selling 1,135 motorcycles. The total included a record 511 new Harley-Davidson motorcycles, securing Black Hills Harley-Davidson as the No. 1 Harley-Davidson dealership in the nation for year-to-date new motorcycle sales.

The achievement was powered by more than 1,200 new and pre-owned, rally-ready motorcycles deployed across Sonic's five Black Hills locations – the largest Harley-Davidson inventory ever assembled for the Rally under Sonic's ownership – and executed through the operational scale of the company's expanded national Harley-Davidson network. The result is a clear operating proof point for Sonic's strategy to build a larger, more connected powersports platform that can offer riders more selection, more access and a stronger guest experience.

"What we accomplished represents far more than another record at the Rally," said David B. Smith, Chairman and Chief Executive Officer of Sonic Automotive. "It validates the strategy behind the platform we are building: expanding our Harley-Davidson footprint, investing in the selection riders want, and giving our teammates the scale and support to execute at the highest level. We are seeing that strategy create a differentiated experience for riders and real momentum for Sonic Powersports."

"The annual Sturgis Motorcycle Rally is one of the most iconic gatherings in motorcycling – an event our customers, dealers and employees look forward to every year – and this year was a tremendous success," said Jonathan Root, Chief Financial and Commercial Officer of Harley-Davidson. "Sonic Powersports helped deliver the kind of unmatched Harley-Davidson customer experience that makes the Rally so special, bringing the scale, selection and commitment it takes to serve riders at the highest level."

2026 Sturgis Motorcycle Rally: Key Facts

- Record retail performance: 1,135 new and pre-owned motorcycles sold, Sonic Powersports' highest Rally sales volume to date.

- Record new-motorcycle sales: 511 new Harley-Davidson motorcycles sold during the Rally.

- Sturgis Harley-Davidson: 348 new and pre-owned motorcycles sold, a dealership record; the location began selling motorcycles only one year ago.

- Rally operating scale: More than 550 Sonic Powersports teammates deployed across five Black Hills locations to support the Rally experience.

"Sturgis is the Super Bowl of motorcycle retail, and our team came ready to compete," said Jeff Dyke, President of Sonic Automotive. "We brought more motorcycles, more teammates and more resources to the Black Hills than ever before. Riders found the selection, the people and the experience they were looking for. The outcome was another record — and more proof of what this growing platform can do."

A National Harley-Davidson Platform Built to Serve Riders

Sonic Powersports continues to be the fastest-growing powersports retailer in the country, with a national Harley-Davidson platform that now spans 20 rooftops and 46 franchises, including 13 Harley-Davidson locations: nine full-service Harley-Davidson dealerships and four Harley-Davidson retail locations focused on apparel and accessories. The network includes Black Hills Harley-Davidson and Sturgis Harley-Davidson in South Dakota, and Mancuso Harley-Davidson and Horny Toad Harley-Davidson in Texas. The 2026 additions included San Diego Harley-Davidson, Falcon's Fury Harley-Davidson in Conyers, Georgia, Space Coast Harley-Davidson in Palm Bay, Florida, Treasure Coast Harley-Davidson in Stuart, Florida, and Raging Bull Harley-Davidson in Durham, North Carolina, extending Sonic's reach in some of the country's most active riding markets and strengthening its ability to serve riders well beyond the Rally.

For more information about Sturgis Harley-Davidson, visit SturgisHD.com. To explore the Sonic Powersports network, visit SonicPowersports.com. Investors can find company information and filings at ir.sonicautomotive.com.

About Sonic Powersports

Sonic Powersports is the powersports division of Sonic Automotive, Inc. and continues to be the fastest-growing powersports retailer in the country. The platform operates 20 rooftops nationwide, representing 46 franchises and premium powersports brands, including Harley-Davidson, Kawasaki, BRP, Polaris, Honda, Suzuki, BMW Motorrad, Yamaha, Ducati and Indian Motorcycle. Sonic Powersports serves riders through new and pre-owned motorcycle sales, parts, service, authentic merchandise, and community experiences.

About Sonic Automotive

For more than 60 years, Sonic Automotive has pursued a single purpose: to deliver an experience for guests and teammates that fulfills dreams, enriches lives and delivers happiness. Founded in 1966 by Bruton Smith, Sonic Automotive today has more than 11,000 teammates across 173 automotive and powersports franchises in 145 locations, representing 24 automotive and 15 powersports brands.

Sonic Automotive was the only automotive and powersports retailer selected for Newsweek's 2026 Most Trustworthy Companies in America list. The company has helped more than 7 million guests purchase vehicles, delivered more than 40 million service experiences and earned more than 1 million five-star reviews by consistently putting people first.

Sonic Automotive. Driven By People. Inspired By Purpose. Learn more at SonicAutomotive.com and ir.sonicautomotive.com.

Contacts

Investor Inquiries: Heath Byrd, Executive Vice President and Chief Financial Officer; Danny Wieland, Vice President, Investor Relations | [email protected]

Media Inquiries: Sonic Automotive Media Relations | [email protected] 

SOURCE Sonic Automotive

Share this article

Funding will accelerate product innovation, go-to-market expansion, and the continued advancement of HAL, context-aware manufacturing AI delivered directly to the point of production.

AKRON, Ohio and NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Harmoni, the Factory Orchestration platform for manufacturers, today announced that it has raised $10 million in Series A funding led by Bessemer Venture Partners. The company also unveiled HAL, its breakthrough artificial intelligence technology built to bring context-aware intelligence directly to the front lines of manufacturing.

Founded in 2023 by David Caputo and Adam Ellis, Harmoni was created to address a fundamental gap in factory technology. U.S. manufacturers are projected to need as many as 3.8 million additional workers by 2033, with nearly half of those positions at risk of going unfilled, as pressure compounds from rising costs, reshoring initiatives, and increasingly complex production environments.

Traditional automation excels at highly repetitive physical tasks, but much of manufacturing still involves variable work, frequent changeovers, and complex coordination among people, machines, and systems. Despite heavy investment in ERP systems, machine connectivity, and automation, factory-floor execution remains fragmented across disconnected systems, manual processes, and outdated workflows.

Harmoni orchestrates work across the factory floor, turning fragmented systems, information, and workflows into coordinated action. At each workcenter, it gives operators a unified command center including the information and tools to execute work correctly and efficiently, while connecting the people, machines, systems, and processes that drive production.

Designed for rapid implementation, Harmoni deploys in weeks and delivers measurable value: less manual work, stronger adherence to approved engineering processes, and real-time visibility into factory performance. Customer results show Harmoni's automations add more than 200 hours of productive time per operator per year by eliminating administrative and other non-productive tasks.

Built on three pillars: automation, process control, and observability, Harmoni uses RFID technology and machine-level workflows to automate non-productive work like labor tracking, ERP transactions, document retrieval, quality reporting, and support requests. Its process control layer ensures operators always have the correct documentation - work instructions, machine programs, checksheets, reducing errors and improving quality. Its observability layer integrates ERP, machine, operator, and RFID data into a real-time view of performance and root-cause issues.

HAL builds on this foundation, applying AI to the live operational context Harmoni captures, including information historically scattered across systems, machines, engineering documents, production records, and institutional knowledge. Because Harmoni already understands the active job, part, machine, process, and engineering requirements, that context reaches HAL automatically. Delivered at the point of production, HAL turns it into relevant intelligence, helping teams understand requirements, diagnose issues, identify risks, and decide what to do next.

"Harmoni was founded on the belief that manufacturers don't need another disconnected application - they need a system that helps work happen correctly, efficiently, and in real time," said David Caputo, Co-Founder of Harmoni. "By bringing automation, process control, and observability together at the workcenter, we help manufacturers eliminate wasted time, prevent errors, and gain control over what is happening across the factory floor. This investment will allow us to accelerate the platform's development, expand our team, and bring Factory Orchestration to more manufacturers."

"Harmoni is building a new operational layer for manufacturing that connects people, machines, and systems across the factory floor," said Kent Bennett, Partner at Bessemer Venture Partners. "Customers are seeing meaningful value from the company's Factory Orchestration platform today, while the operational context Harmoni creates provides a powerful foundation for delivering AI directly into production workflows. We are excited to partner with David, Adam, and the Harmoni team as they build an important new category in manufacturing technology."

About Harmoni

Harmoni is a Factory Orchestration System that helps manufacturers eliminate wasted time, prevent errors, and gain real-time visibility into operations. Built on the pillars of automation, process control, and observability, Harmoni connects operators, machines, engineering systems, and enterprise software through a unified platform that improves productivity, quality, and operational efficiency. Harmoni is also the developer of HAL, context-aware manufacturing AI delivered from the executive office to the front lines of production. Based in Akron, Ohio, and New York, New York, Harmoni helps manufacturers modernize shop-floor execution and build more connected, intelligent factories. For more information, visit www.harmoni.io.

About Bessemer Venture Partners

Bessemer Venture Partners helps entrepreneurs lay strong foundations to build long-standing companies. With more than 155 IPOs and 450-plus portfolio companies across industries, Bessemer supports founders and CEOs from seed through every stage of growth. Bessemer has backed industry-defining companies including Anthropic, Abridge, Canva, LinkedIn, Perplexity, Pinterest, Rocket Lab, Shopify, ServiceTitan, Toast, and Twilio, and has $20 billion in assets under management. Bessemer invests globally, with investment teams located in San Francisco, Silicon Valley, New York, Boston, London, Bangalore, and Tel Aviv. For more information, visit www.bvp.com.

SOURCE Harmoni

Share this article

Research initiative will evaluate how collective defense solutions can strengthen cooperative utility networks nationwide for more resilient grid security

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Cyware, the leader in agentic AI-powered operationalized threat intelligence and collective defense, today announced it is supporting the research arm of the National Rural Electric Cooperative Association (NRECA), the national trade association representing nearly 900 electric cooperatives with its Department of Energy (DOE) funded effort to expand OT monitoring across the electric sector.

"Information sharing within Operational Technology (OT) cybersecurity can be challenging," said Tom Stockmeyer, Managing Director Government and Critical Infrastructure, Cyware. "While many organizations have made efforts to share OT threat information, the industry wants to improve. We look forward to supporting NRECA on this important initiative to improve community-wide automated access to high-value OT alerts between SOC teams of participating cooperatives."

"A key goal at NRECA is to help rural electric cooperatives strengthen their cybersecurity standing through greater visibility, collaboration and shared intelligence," said Adrian McNamara, Principal Cybersecurity Program Manager and ICS-REC project lead at NRECA. "This project is focused on standardizing the collection, correlation, and normalization of data from participating rural cooperatives to enable centralized analysis. By creating a common framework for analysis and information sharing, we will be able to provide more actionable insights back to the cooperative community which means faster threat detection, stronger coordination and a more resilient ecosystem."

To date, participating utilities have reported measurable improvements in visibility, logging capabilities, and alerting. Looking ahead, the project will focus on closing the market gap for smaller, less-resourced utilities and enabling automatic sharing of validated findings with the broader community.

For more information, visit: https://www.cooperative.com/programs-services/bts/research/ics-rec/Pages/default.aspx.

About Cyware

Cyware is leading the industry in operationalized threat intelligence and collective defense, helping security teams transform threat intelligence from fragmented data points to actionable, real-time decisions. We unify threat intelligence management, intel sharing and collaboration, as well as orchestration and automation — eliminating silos and enabling organizations to outmaneuver adversaries faster and more effectively.

From enterprises to government agencies and ISACs, Cyware empowers defenders to turn intelligence into impact.

To learn more about Cyware, visit www.cyware.com.

Disclaimer: NRECA does not endorse any commercial product or service.

Media Contact for Cyware:

Danielle Ostrovsky

Hi-Touch PR for Cyware

[email protected]

SOURCE Cyware

Share this article

Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies

PRINCETON, N.J. and SUZHOU, China, Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its subsidiary, HJB, have entered into a technology licensing and strategic collaboration agreement with WuXi Biologics. Under the agreement, Transcenta will grant WuXi Biologics and its affiliates a non-exclusive license to certain technologies relating to Transcenta's Highly Intensified Continuous Bioprocessing ("HiCB") platform and ExcelPro cell culture media. Transcenta will receive an upfront payment of RMB 10 million and will be eligible for milestone payments upon the achievement of specified conditions. Through this collaboration, WuXi Biologics will become Transcenta's strategic partner for CMC development and supporting molecules across Transcenta's development pipeline.

HiCB platform integrates intensified continuous perfusion upstream processing with hybrid continuous downstream purification, enabling a step-change in productivity, achieving significant increase in productivity compared with conventional fed-batch processes, while maintaining superior product quality through shorter residence time and optimized culture conditions. HiCB can significantly reduce cost of goods, lower capital investment, and enable agile and just-in-time production. It also provides a solution for improving recovering yield and product quality for complex biologics.

This collaboration is part of Transcenta's continued efforts to advance partnerships for its HiCB technology platform and broaden its application to address CMC challenges for complex biologic molecules. It also offers a flexible approach to rapidly expand production capacity. Transcenta plans to further unlock the commercial value of the HiCB platform through external licensing and industry partnerships.

About Transcenta

Transcenta (06628.HK) is a clinical-stage biopharmaceutical company with fully integrated capabilities in biologics discovery, translational research, clinical and process development.

Headquartered in Suzhou, Transcenta has established a global presence with R&D centers and clinical development centers across China and internationally. Transcenta is developing a diversified pipeline of over ten therapeutic antibody candidates spanning oncology, bone and kidney disorders.

For more information, please visit www.transcenta.com or follow our official LinkedIn page: Transcenta Therapeutics.

Investor Relations: [email protected]

Public Relations: [email protected]

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics — from concept to commercialization — for the benefit of patients worldwide.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Transcenta, are intended to identify certain of such forward-looking statements. Transcenta does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Transcenta with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Transcenta's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Transcenta's competitive environment and political, economic, legal and social conditions.

Transcenta, the Directors and the employees of Transcenta assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

SOURCE Transcenta Therapeutics

Share this article

Findhelp's specialty exchange services support social care referral and reporting under the Maryland Rural Health Transformation Program

AUSTIN, Texas, Sept. 9, 2026 /PRNewswire/ -- Findhelp, the nation's leading social care technology platform, today announced it is the first specialty exchange that has registered with the Maryland Health Care Commission (MHCC).

Findhelp is uniquely positioned to advance the goals of the Maryland Rural Health Transformation Program (RHTP) by helping grant awardees easily navigate social risk screening, referrals, data exchange, and reporting requirements. By equipping health care providers and community-based organizations (CBOs) with these specialized technical capabilities, Findhelp can help reduce barriers to care coordination and strengthen connections between rural patients and essential non-medical resources.

Streamlining Whole Person Care Across Maryland

As a dedicated partner to health information exchange (HIE) organizations like CRISP, Maryland's State-Designated HIE, Findhelp supports the exchange of referrals and social care information. By integrating social needs screening and referral processes into electronic health record systems, Findhelp allows providers to connect patients with community resources and receive information about referral outcomes within existing workflows. This can give health care organizations a more complete view of patients' needs, support coordination between clinical and community partners, and help address non-medical drivers of health.

"Building on existing data-sharing infrastructure and partnerships can promote greater sharing of social needs information and support the State's broader health care transformation goals," said Douglas Jacobs, MD, MPH, Executive Director at MHCC. "Findhelp's registration as a specialty exchange represents an important step toward connecting clinical care with community-based resources and interoperability across platforms."

Supporting Maryland's Rural Health Transformation Program

Findhelp's interoperable platform is designed to simplify how care teams collect, exchange, and report social care information across systems in a standardized way. These capabilities can support RHTP grant recipients as they coordinate referrals, monitor outcomes, and work to align with Maryland's existing health information exchange infrastructure. Findhelp's integration with CRISP supports bidirectional data exchange, allowing participating clinicians to review community referral information and outcomes within their existing workflows.

Strengthening Regional Data Sharing with CRISP

Findhelp's role in Maryland reflects its commitment to complement traditional HIEs rather than replace them. Findhelp users who choose to share information through CRISP can allow other authorized CRISP users to see community program information, referral status updates, and referring provider information. This gives participating providers a more complete view of patients' interactions with community-based services, regardless of where care was initiated.

"We're proud to achieve registration status with MHCC," said Jaffer Traish, Chief Operating Officer at Findhelp. "By connecting directly into EHR workflows and feeding social care insights into regional partners like CRISP, we're helping Maryland advance RHTP goals while keeping care human, efficient, and accessible."

Findhelp offers a solution to primary care practices and health systems looking to expand access to social care services and makes it easy for organizations to deliver whole person care and support rural health transformation across the State. The platform has demonstrated it meets rigorous, nationally recognized standards for privacy and security and has the advanced technical capabilities necessary to support the secure, interoperable exchange of electronic health information across clinical and community networks. Maryland RHTP grant recipients can deploy Findhelp's social care infrastructure immediately; it links seamlessly with EHRs without any upfront technical integration.

About Findhelp

Findhelp is the leading social care platform, powering a connected safety net. We enable health systems, governments, payers, and more to identify social needs, coordinate services, and manage benefits enrollment through a unified digital infrastructure. Our technology provides a smarter, faster, and more efficient way to deliver social care—at scale. Visit company.findhelp.com to learn more about our solutions.

SOURCE Findhelp

Share this article

Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-1726

CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced results from a preclinical tissue distribution study demonstrating that DA-1726-derived radioactivity is slowly absorbed and extensively distributed throughout the body following subcutaneous administration, with broad tissue distribution and the highest tissue exposure observed in adipose (fat) tissue.

Data from the study showed that tissue-to-plasma ratios increased over time, indicating prolonged retention of DA-1726-derived radioactivity in tissues relative to plasma. Consistent with this finding, the greatest exposure outside of the injection site occurred in abdominal, subcutaneous and brown fat, as well as the liver.

"We believe these findings provide important mechanistic support for the differentiated profile we continue to observe with DA-1726," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "In our previously reported Phase 1 study, patients receiving the 48 mg dose of DA-1726 achieved a mean reduction in waist circumference of 9.8 cm after only eight weeks of treatment (Day 54). We believe the preferential distribution of DA-1726-derived radioactivity to adipose tissue observed in this preclinical study provides an important biological rationale that is consistent with these encouraging clinical findings. In addition, the prolonged retention of DA-1726-derived radioactivity in tissues observed throughout the study may contribute to the sustained pharmacokinetic exposure of DA-1726 and may also help explain the excellent tolerability profile observed across our clinical studies, to date. Together, these findings further reinforce our confidence in the unique potential of DA-1726 as a next-generation obesity therapy. As patients in our ongoing 24-week dose-titration study continue to receive extended treatment at their highest achieved dose levels, we look forward to evaluating whether longer treatment can further enhance reductions in waist circumference, weight loss and other important cardiometabolic measures. We anticipate reporting 16-week topline data in the fourth quarter of this year, followed by 24-week topline results in the first quarter of 2027."

The preclinical study data also demonstrated prolonged retention of DA-1726-derived radioactivity in tissues through the final 144-hour assessment, consistent with the prolonged pharmacokinetic profile supporting once-weekly dosing of DA-1726. In addition, only minimal radioactivity was detected in the central nervous system, consistent with the limited brain penetration typically observed with peptide-based therapies.

About DA-1726

DA-1726 is a novel GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in preclinical mouse models, resulted in improved weight loss compared to semaglutide (Wegovy®), a leading GLP-1 receptor agonist. Additionally, in preclinical mouse models, DA-1726 elicited similar weight reduction, while consuming more food, compared to tirzepatide (Zepbound®) and survodutide (a drug with the same MOA), while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.

About MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119). In preclinical studies, vanoglipel demonstrated a positive metabolic effect on glucose and lipid control, and also proved differentiated hepatic benefits reducing hepatic steatosis, hepatic inflammation, and liver fibrosis regardless independent of metabolic improvement. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Forward Looking Statements

Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia's ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of preclinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

MetaVia

Marshall H. Woodworth

Chief Financial Officer

+1-857-299-1033

[email protected]

Rx Communications Group

Michael Miller

+1-917-633-6086

[email protected]

SOURCE MetaVia Inc.

Share this article

Albaron Partners Completes Sale of Prime Psychiatry to Beacon Behavioral Partners

Prime Psychiatry to Continue Its Growth as Part of Beacon Behavioral Partners

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Albaron Partners, LP ("Albaron"), a middle-market private equity firm, is pleased to announce that it has completed the sale of Prime Wellness LLC d/b/a Prime Psychiatry ("Prime Psychiatry"), a Texas-based leader in outpatient and interventional psychiatry services, to Beacon Behavioral Partners ("Beacon").

In 2022, Albaron partnered with Dr. Efosa Airuehia, founder of Prime Psychiatry, to grow the practice into a regional leader in outpatient and interventional psychiatric care. As part of Beacon's national behavioral health platform, Prime Psychiatry will expand its established Texas presence, positioning both companies for their next phase of growth. "We've greatly valued our partnership with Dr. Airuehia in building Prime Psychiatry into what it is today," said Debo Adesina, partner at Albaron. "We believe that joining Beacon's platform will further accelerate Prime Psychiatry's ability to scale its clinical offerings to patients across Texas and beyond."

Cozen O'Connor P.C. served as sell-side legal counsel to Albaron and Prime Psychiatry, while Citizens Capital Markets & Advisory acted as sell-side financial advisor on the transaction.

About Prime Psychiatry

With operations in DFW and Austin, TX, Prime Psychiatry is a regional leader in outpatient psychiatric services for children, adolescents, and adults. Prime Psychiatry offers various treatment options including anxiety treatment, depression treatment, medication management, TMS, and Spravato (https://primepsychiatrymd.com).

About Beacon

Beacon Behavioral Partners is a physician-driven organization supporting a growing network of independent psychiatric practices across the U.S. They partner with providers to deliver exceptional behavioral healthcare in their communities by removing operational burdens, investing in smart growth, and upholding clinical autonomy. With decades of healthcare management experience and a commitment to data-driven decision-making, their mission is to set the standard for interventional psychiatry through trusted local practices, accountable leadership, and continuous innovation. Beacon helps partners scale sustainably while focusing on what matters most: delivering high-quality, patient-centered care (beaconbhpartners.com).

About Albaron

Founded in 2017, Albaron is an operationally focused, middle-market healthcare private equity firm. Its dedicated team of healthcare investors and seasoned operators partners with founders and management teams to scale their businesses and build leading platforms within their respective specialties. Albaron is currently investing out of its latest fund, a $185 million vehicle that closed in May 2026 (https://albaronpartners.com).

SOURCE Albaron Partners

Share this article